Clinical trial
Valopicitabine When Administered Alone and in Combination With Interferon to…
NCT00120835 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00120835 |
|---|---|
| Title | Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C |
| Official title | An Open-Label, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and the Antiviral Activity of NM283 When Administered Alone and in Combination With Pegylated Interferon Alfa 2b to Treatment-Naive Adults With Genotype-1 Chronic Hepatitis C |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | valopicitabine, pegylated interferon |
| Start date | Jul 1, 2004 |
| First posted | Jul 19, 2005 |
| Last update posted | Jun 10, 2010 |
| Countries | Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: